Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2b + temozolomide
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular, Intravenous
01
Overview
This is a combination therapy consisting of interferon alfa-2b and temozolomide. Interferon alfa-2b is a recombinant cytokine with immunomodulatory, antiproliferative, and antiangiogenic properties. It acts by stimulating the innate immune response and has demonstrated antitumor activity in various malignancies. Temozolomide is an oral alkylating agent that induces DNA damage in tumor cells by methylating guanine residues, leading to cell cycle arrest and apoptosis. The combination has been investigated primarily for the treatment of malignant melanoma and high-grade glioma (HGG), where it aims to enhance antitumor efficacy through both direct cytotoxic effects (temozolomide) and immune modulation (interferon alfa-2b). Clinical studies have shown that this regimen can be administered safely with manageable toxicity profiles[1][3][4][5].
- Other names
- interferon alpha-2b + temozolomideIFN-alpha 2b + temozolomideIFN-α2b + temozolomide
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)DNA
Beyond the preview
Go deeper on interferon alfa-2b + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2b + temozolomide.